Screener
SG&A at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Zevra Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.
The source filing: Zevra Therapeutics, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 5:19 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001434647-26-000068
| Line item | Three months ended June 30, 2026 | Three months ended June 30, 2025 | Six months ended June 30, 2026 | Six months ended June 30, 2025 |
|---|---|---|---|---|
| Gain on sale of future royalties, intellectual property, and other assets, net | — | — | 43,314 | — |
| Operating expenses: | ||||
| Research and development | (4,486) | (3,433) | (8,878) | (6,691) |
| Selling, general and administrative | (16,559) | (20,782) | (37,342) | (40,327) |
| Total operating expenses | (21,045) | (24,215) | (46,220) | (47,018) |
| Income (loss) from operations | 16,777 | (71,039) | 68,923 | (76,401) |
| Other (expense) income: | ||||
| Gain on sale of PRV | — | 148,325 | — | 148,325 |
ITEM 1.FINANCIAL STATEMENTS
FAQ
- What is Zevra Therapeutics, Inc.'s SG&A?
- Zevra Therapeutics, Inc. (ZVRA) reported SG&A of $16.56M in Q2 2026.
- How has Zevra Therapeutics, Inc.'s SG&A changed year-over-year?
- Zevra Therapeutics, Inc.'s SG&A decreased by 20.3% year-over-year, from $20.78M to $16.56M.
- What is the long-term trend for Zevra Therapeutics, Inc.'s SG&A?
- Over 3 years (2022 to 2025), Zevra Therapeutics, Inc.'s SG&A has grown at a 72.8% compound annual growth rate (CAGR), from $15.04M to $77.62M.
- What does SG&A mean?
- Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.
Ask your AI about Zevra Therapeutics, Inc.'s sg&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude